Nevertheless, the frequency of the somatic mutations that we detected both in IDO1 and HLA-DRA, suggests that these are common events taking place in skin melanoma and could be involved in hindering patient response to ICI therapies. The gene discussed is IDO1; the disease is cutaneous melanoma.